Rodman & Renshaw Maintains Market Outperform Rating and $12 PT on Alnylam Pharmaceuticals

A report form Rodman & Renshaw reiterates its Market Outperform rating and $12 price target on Alnylam Pharmaceuticals

. The report states, “We believe that the next 12-18 months will contain key pipeline value-drivers. As a result,in our opinion, the true value of Alnylam's RNAi technology will soon be better understood. First up will be clinical data from the Phase Ib trial for the ALN-TTR program, which will be presented November 20-22, 2011, at the International Symposium on Familial Amyloidotic Polyneuropathy conference in Kumamoto, Japan." ALNY closed yesterday at $8.12.